GET DAILY SIGNALSAC Immune SA (ACIU): Could It Reach $9 With +300% Upside?
Key Takeaways
- The central target of $9 is the arithmetic mean of three attributable analyst price targets — $12, $8, and $7 — reviewed for this analysis.
- At a latest price near $2.25, reaching $9 would require upside of roughly 300%, a very large move even for a high-risk biotech.
- Attributable targets range from $7.00 (Jefferies, Buy) to $12.00 (H.C. Wainwright, Buy), with BTIG at $8.00 (Buy), reflecting wide disagreement about the pipeline's value.
- The strongest supporting factor is positive Phase 2 data for the ACI-7104 Parkinson's vaccine and validation of the company's platform, plus a cash runway into late 2027.
- The biggest risks are clinical-trial failure, continued operating losses, dilution, and a market that has repeatedly repriced the shares below analyst objectives.
- Readers can find more detail on this ticker's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
- Explore Trending AI Robots for AI-driven tools that scan markets for changing opportunities.
Analyst Price Targets and Consensus View
Three current, attributable analyst price targets were identified for this analysis. Andrew Fein of H.C. Wainwright reiterated a Buy with a $12.00 target in September 2026; Thomas Shrader of BTIG reiterated a Buy with an $8.00 target in September 2026; and Jefferies maintained a Buy with a $7.00 target in March 2026. The arithmetic mean of these three figures is $9.00, which serves as the central target here, with an approximate range of $7.00 to $12.00. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Notably, this range is wide — the highest target is roughly 70% above the lowest — reflecting genuine disagreement about how much of ACIU's pipeline value will be realized. Third-party consensus figures vary (some providers report averages near $7.50 to $8.60) because they include different analysts; the $9 figure is this analysis's own calculation from attributable targets, not an official published consensus. H.C. Wainwright's Buy rests on Phase 2 ACI-7104 data validating the platform, while BTIG's valuation leans on a discounted-cash-flow view of a diversified neuroscience pipeline and cash runway into late 2027.
Current Market Position and Path Toward the Target
With the latest price near $2.25, moving to $9.00 implies upside of approximately 300% — a very large move that would require the stock to nearly quadruple. The shares sit toward the lower end of a 52-week range of roughly $2.03 to $4.00 and below their 50-day and 200-day moving averages, indicating the market has been discounting the company's fundamentals despite upbeat clinical news. From what I see, a path toward $9 would likely require successive, de-risking clinical readouts rather than any single catalyst.
AC Immune SA reported second-quarter revenue of about $18.67 million versus roughly $9.59 million expected, and a modest EPS beat, but the company remains unprofitable with a negative net margin. Reaching the target would depend on continued progression of programs such as ACI-7104 in Parkinson's, ACI-24 for Alzheimer's, and the ACI-19764 NLRP3 inhibitor, alongside partner milestones from collaborators including Genentech (Roche), Janssen, and Eli Lilly.
Factors That Could Support a Move to the Target
Positive interim Phase 2 data for ACI-7104 in early Parkinson's disease — meeting primary endpoints with strong immunogenicity and improved CNS exposure — has been cited by analysts as validating the company's SupraAntigen platform. The company's cash position of roughly $75 million and a runway extending into late 2027 reduce near-term financing risk. Multiple collaborations with large pharmaceutical partners provide non-dilutive funding and external validation, while a diversified pipeline across Alzheimer's, Parkinson's, and neuroinflammation offers several potential value inflection points.
Risks That Could Hold ACIU Back
Clinical-stage biotech carries binary risk: a failed or ambiguous trial in any lead program could sharply compress the valuation. The company continues to post net losses and negative free cash flow, leaving it dependent on partners and future capital raises that could dilute shareholders. The wide analyst target range itself signals uncertainty, and the stock's persistent discount to every published target — including a 52-week high of only $4.00 — reflects skepticism that the pipeline will convert into approved products. Small sample sizes and exploratory endpoints in recent readouts add further caution.
Technical Levels to Watch
The shares have carved a durable trading band between the 52-week low near $2.03 and the 52-week high near $4.00. The $4.00 area stands as the most meaningful resistance level, and the $2.00–$2.10 zone represents key support. The stock currently trades below its 50-day and 200-day moving averages, indicating a weak longer-term trend structure; a sustained move above $4.00 would be a notable structural signal on any path toward the $9 target.
Time Horizon and Key Catalysts to Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms may apply different frameworks. Investors should watch the next earnings report, clinical data updates for ACI-7104 and ACI-24, the ACI-19764 Phase 1 results, and any partner milestone or licensing news. Analyst target revisions — particularly any changes from H.C. Wainwright, BTIG, or Jefferies — and financing activity are also worth monitoring closely. I’m watching this closely for any shifts in momentum.
Final Assessment
Can AC Immune (ACIU) reach $9? The target reflects the mean of three attributable analyst objectives ($7, $8, and $12) and would require a roughly 300% advance from the current price near $2.25 — a very large move that is not supported by the stock's recent trading range. The bull case rests on platform validation from positive Parkinson's Phase 2 data and a funded runway into late 2027, while the bear case centers on binary clinical risk, ongoing losses, and a market that has persistently valued the shares far below analyst targets. The wide target spread underscores genuine uncertainty. Investors should weigh upcoming clinical readouts and partner developments rather than treat any single price objective as a forecast.
Leveraging Tickeron’s AI Daily Buy/Sell Signals
In my research process, I often turn to Tickeron’s AI Daily Buy/Sell Signals to monitor volatile names like this one. The tool uses artificial intelligence to generate Buy, Sell, or Hold signals based on technical behavior and market conditions, helping me spot potential shifts more efficiently alongside my own analysis of clinical and financial data.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ACIU in upward trend: price may jump up because it broke its lower Bollinger Band on October 26, 2026
ACIU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 35 of 37 cases where ACIU's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 66 cases where ACIU's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
Following a +4.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACIU advanced for three days, in 171 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACIU as a result. In 66 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
ACIU moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ACIU crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACIU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for ACIU entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 43 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. ACIU’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.361) is normal, around the industry mean (3.037). P/E Ratio (-5.233) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.070) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (12.547) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACIU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutic and diagnostic products to prevent and modify diseases caused by misfolding proteins
Industry Biotechnology
Advertisement